Literature DB >> 15891521

Employees with overactive bladder: work loss burden.

Eric Q Wu1, Howard Birnbaum, Maryna Marynchenko, Milena Mareva, Todd Williamson, David Mallett.   

Abstract

OBJECTIVE: This study assessed the indirect work loss costs to employers as the result of employees with overactive bladder (OAB).
METHODS: Study samples were drawn from an administrative database of 1.2 million beneficiaries, including medical and disability claims (1999-2002). OAB employees were compared with matched employees without OAB.
RESULTS: OAB was associated with higher annual occurrences of work loss (P < 0.01). Employees with OAB had 2.2 excess work loss days as the result of medically related absenteeism and 3.4 excess days as the result of disability compared with employees without OAB (P < 0.01 for both comparisons). Employees with OAB had increased risk of disability (P < 0.01), and female employees with OAB had a higher risk of disability than male employees (P < 0.01).
CONCLUSIONS: This study found that OAB was associated with work loss costs to employers resulting from increased number of employee sick days and increased risk of employee disability.

Entities:  

Mesh:

Year:  2005        PMID: 15891521     DOI: 10.1097/01.jom.0000161744.21780.c1

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  13 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  The Burden of Overactive Bladder on US Public Health.

Authors:  W Stuart Reynolds; Jay Fowke; Roger Dmochowski
Journal:  Curr Bladder Dysfunct Rep       Date:  2016-01-23

3.  Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial.

Authors:  Kirill Vladimirovich Kosilov; Sergey Loparev; Irina Kuzina; Olga Shakirova; Nataliya Zhuravskaya; Alexandra Lobodenko
Journal:  Ther Adv Urol       Date:  2016-06-03

4.  Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.

Authors:  Antoni Sicras-Mainar; Ruth Navarro-Artieda; Amador Ruiz-Torrejón; Marc Sáez-Zafra; Gabriel Coll-de Tuero
Journal:  Clin Drug Investig       Date:  2015-12       Impact factor: 2.859

Review 5.  Oxybutynin: past, present, and future.

Authors:  Kelly Jirschele; Peter K Sand
Journal:  Int Urogynecol J       Date:  2012-09-14       Impact factor: 2.894

6.  Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.

Authors:  Sender Herschorn; Jameel Nazir; Barbara Ramos; Zalmai Hakimi
Journal:  Can Urol Assoc J       Date:  2017 Mar-Apr       Impact factor: 1.862

Review 7.  Global perspective of treatment failures.

Authors:  Sender Herschorn
Journal:  Can Urol Assoc J       Date:  2013-09       Impact factor: 1.862

8.  Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.

Authors:  Laura T Pizzi; Amy Talati; Eric Gemmen; Naomi V Dahl; Thomas J Bunz; Peter K Sand
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 9.  Pharmacotherapy of urinary incontinence.

Authors:  Anastasios Athanasopoulos; Petros Perimenis
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-11-12

10.  Comparison of objective and subjective factors in the adherence to antimuscarinics when treating overactive bladder in employed persons.

Authors:  Kirill Vladimirovich Kosilov; Sergey Loparev; Irina Kuzina; Alexandra Prokofyeva
Journal:  Ther Adv Urol       Date:  2017-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.